3,10-dihydroxy-2-naphthacene Carboxamide Or Derivative (e.g., Tetracycline, Etc.) Doai Patents (Class 514/152)
  • Patent number: 8992896
    Abstract: A topical therapeutic hydrophobic breakable composition includes a carrier comprising (a) about 60% to about 99% by weight of at least one hydrophobic oil; (b) at least one viscosity-modifying agents selected from the group consisting of a fatty alcohol, a fatty acid and a wax; and (c) a tetracycline antibiotic, characterized in that at least part of the tetracycline antibiotic is suspended in the composition; the viscosity of the composition is at least about 30% higher than the viscosity of the carrier without the tetracycline antibiotic; and is higher than the viscosity of the hydrophobic oil and the tetracycline antibiotic without the viscosity modifying agents. The tetracycline is chemically stable in the composition for at least six months; wherein more than about 90% of the tetracycline has not broken down. The composition is packaged as a breakable foam that breaks easily upon application of shear force.
    Type: Grant
    Filed: August 27, 2014
    Date of Patent: March 31, 2015
    Assignee: Foamix Pharmaceuticals Ltd.
    Inventors: Dov Tamarkin, Elana Gazal, Irakliy Papiashvili, Yohan Hazot, David Schuz, Rita Keynan
  • Publication number: 20150080324
    Abstract: The present invention relates to antimalarial compounds and their use against protozoa of the genus Plasmodium, including drug-resistant Plasmodia strains. This invention further relates to compositions containing such compounds and a process for making the compounds.
    Type: Application
    Filed: November 25, 2014
    Publication date: March 19, 2015
    Inventors: Gavin David Heffernan, David Penman Jacobus, Guy Alan Schiehser, Hong-Ming Shieh, Wenyi Zhao
  • Publication number: 20150071981
    Abstract: The present invention provides compositions for extended release of an active ingredient, comprising a lipid-saturated matrix formed from a biodegradable polymer. The present invention also provides methods of producing the matrix compositions and methods for using the matrix compositions to provide controlled release of an active ingredient in the body of a subject in need thereof.
    Type: Application
    Filed: October 26, 2014
    Publication date: March 12, 2015
    Inventor: Noam EMANUEL
  • Publication number: 20150057254
    Abstract: Disclosed are once-daily formulations containing tetracyclines, especially doxycycline. Such formulations are useful, for instance, for the treatment of collagenase destructive enzyme-dependent diseases, such as periodontal disease and acne, and acute and chronic inflammatory disease states, such as rosacea and arthritis.
    Type: Application
    Filed: March 19, 2014
    Publication date: February 26, 2015
    Applicant: Supernus Pharmaceuticals, Inc.
    Inventors: Rong-Kun Chang, Arash Raoufinia, Niraj Shah
  • Publication number: 20150056149
    Abstract: A topical therapeutic hydrophobic breakable composition includes a carrier comprising (a) about 60% to about 99% by weight of at least one hydrophobic oil; (b) at least one viscosity-modifying agents selected from the group consisting of a fatty alcohol, a fatty acid and a wax; and (c) a tetracycline antibiotic, characterized in that at least part of the tetracycline antibiotic is suspended in the composition; the viscosity of the composition is at least about 30% higher than the viscosity of the carrier without the tetracycline antibiotic; and is higher than the viscosity of the hydrophobic oil and the tetracycline antibiotic without the viscosity modifying agents. The tetracycline is chemically stable in the composition for at least six months; wherein more than about 90% of the tetracycline has not broken down. The composition is packaged as a breakable foam that breaks easily upon application of shear force.
    Type: Application
    Filed: August 27, 2014
    Publication date: February 26, 2015
    Inventors: Dov Tamarkin, Elana Gazal, Irakliy Papiashvili, Yohan Hazot, David Schuz, Rita Keynan
  • Publication number: 20150050340
    Abstract: The present invention provides compositions for extended release of an active ingredient, comprising a lipid-saturated matrix formed from a biodegradable polymer. The present invention also provides methods of producing the matrix compositions and methods for using the matrix compositions to provide controlled release of an active ingredient in the body of a subject in need thereof.
    Type: Application
    Filed: October 26, 2014
    Publication date: February 19, 2015
    Inventor: Noam EMANUEL
  • Publication number: 20150045329
    Abstract: The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for tetracycline compounds such as blocking tetracycline efflux and modulation of gene expression.
    Type: Application
    Filed: May 19, 2014
    Publication date: February 12, 2015
    Applicant: Paratek Pharmaceuticals, Inc.
    Inventors: Mark L. Nelson, Kwasi Ohemeng, Paul Abato, Victor Amoo, Haregewein Assefa, Joel Berniac, Beena Bhatia, Todd Bowser, Jackson Chen, Mark Grier, Laura Honeyman, Mohamed Y. Ismail, Oak K. Kim, Jude Mathews, Rachid Mechiche
  • Publication number: 20150044297
    Abstract: The invention relates to a novel galenical system for taste masking, protecting an active substance, in particular in an acid medium, modulating releasing properties, masking mucous irritability and toxicity of certain active substances, for preparing aqueous forms which have a masked taste, are stable and pH independent. Said invention also relates, in particular to a galenical system which is embodied in the form of lipidic solid particles and strictly hydrophobic and devoid of water, surface active agents, emulsifiers, solvent traces and which is characterized in that it comprises at least one type of hydrophobic wax and at least one type of fatty non-neutralised acid.
    Type: Application
    Filed: October 27, 2014
    Publication date: February 12, 2015
    Inventors: Karim Ioualalen, Rose-Anne Raynal
  • Publication number: 20150038851
    Abstract: Provided herein are methods of diagnosing meibomian gland dysfunction (MGD), determining the severity of meibomian gland dysfunction in a subject, evaluating efficacy of treatment of MGD in a subject, selecting a subject for treatment of MGD, and selecting a subject for participation in a clinical study.
    Type: Application
    Filed: February 21, 2013
    Publication date: February 5, 2015
    Inventors: Pedram Hamrah, Yureeda Qazi
  • Patent number: 8945516
    Abstract: A substantially surface active agent free composition which includes a hydrophobic solvent, and/or a petrolatum, a paraffin wax and/or a fatty alcohol, a fatty acid and/or a wax and/or shea butter, with and without a propellant. A substantially surface active agent free composition, further comprising, a tetracycline antibiotic, or a vitamin D derivative, or one or more other active agents. A method of treatment using a substantially surface active agent free composition.
    Type: Grant
    Filed: October 1, 2010
    Date of Patent: February 3, 2015
    Assignee: Foamix Pharmaceuticals Ltd.
    Inventors: Dov Tamarkin, Elana Gazal, Yohan Hazot, David Schuz, Rita Keynan, Nukri Papiashvili
  • Patent number: 8945623
    Abstract: The invention provides compositions, kits, and methods for treatment of neuronal injury. In one embodiment, the composition comprises a biomembrane sealing agent, such as PEG, and a bioactive agent, such as a magnesium compound. The biomembrane sealing agent and/or the bioactive agent an intravenous administration, an intramuscular administration, an intrathecal administration, a subcutaneous administration, an epidural administration, a parenteral administration, a direct application onto or adjacent to a site of the pathological condition, and any combinations thereof. Alternatively, the biomembrane sealing agent and/or the bioactive agent may be delivered from a pump or an implant.
    Type: Grant
    Filed: May 3, 2006
    Date of Patent: February 3, 2015
    Assignee: Warsaw Orthopedic, Inc.
    Inventors: Josee Roy, William F. McKay, Jeffrey C. Marx
  • Patent number: 8946196
    Abstract: Methods for the synthesis and purification of 9-amino alkyl tetracycline compounds are described.
    Type: Grant
    Filed: September 30, 2013
    Date of Patent: February 3, 2015
    Assignee: Paratek Pharmaceuticals, Inc.
    Inventors: Sean M. Johnston, Tadeusz Warchol
  • Publication number: 20150025025
    Abstract: An immuno-modulating composition including an organic compound and a metal chelator or a metal ion. Also disclosed is a method for treating a disease or condition in man and animals with the composition. Further, a method for delivering a growth factor or a homeostasis-maintaining factor to its receptor is provided.
    Type: Application
    Filed: July 19, 2013
    Publication date: January 22, 2015
    Inventor: Ricky McCullough
  • Publication number: 20150023975
    Abstract: Matrix metalloproteases (MMPs) play many important roles in normal and pathological remodeling processes including atherothrombotic disease, inflammation, angiogenesis and cancer. This invention relates to the activation of protease-activated receptor-1 (PAR-1) by endogenous platelet MMP-1 collagenase on the surface of platelets. Exposure of platelets to fibrillar collagen converts the surface-bound pro-MMP-1 zymogen to active MMP-1, which promotes aggregation through PAR-1. MMP-1 is shown to cleave the PAR-1 extracellular domain at a novel site, which then strongly activates Rho-GTP signaling pathways, cell shape change and motility, and MAPK signaling. Blockade of MMP-PAR1 suppresses thrombogenesis under arterial flow conditions and inhibited thrombosis in animals. These studies provide a link between matrix-dependent activation of metalloproteases and platelet-G protein signaling and identify MMP-1/PAR-1 as a new target for the treatment and prevention of arterial thrombosis and other thrombotic diseases.
    Type: Application
    Filed: August 14, 2014
    Publication date: January 22, 2015
    Inventors: Athan Kuliopulos, Georgios Koukos
  • Patent number: 8936795
    Abstract: A liquid embolic material may include a mixture of a first solution comprising between about 1.2% and about 2.5% weight per volume (w/v) carboxymethyl chitosan (CCN) in a first solvent and a second solution comprising between about 1.2% and about 2.5% w/v oxidized carboxymethyl cellulose (OCMC) in a second solvent. The liquid embolic material may be used to embolize a targeted embolization location by mixing the first solution and the second solution to form a liquid embolic material (or hydrogel precursor material), introducing the hydrogel precursor material to a targeted embolization location within a body of a patient, and allowing the CCN and the OCMC to react to form the hydrogel material and embolize the targeted embolization location.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: January 20, 2015
    Assignee: Regents of the University of Minnesota
    Inventors: Jafar Golzarian, Lihui Weng
  • Publication number: 20150004216
    Abstract: A medicant composition is provided. The composition includes a film layer and a powder matrix layer. The powder matrix layer includes a medicant. The powder matrix layer is applied to the film layer by admixing particulate to form a powder matrix and by then applying the powder matrix to the film layer by any desired method. The composition of the powder matrix is varied to alter the dissolution rate of the medicant, the adhesion of the medicant composition, and other physical properties of the powder matrix. The powder matrix layer can be cured.
    Type: Application
    Filed: September 19, 2014
    Publication date: January 1, 2015
    Inventor: Robert Steven Davidson
  • Publication number: 20140377347
    Abstract: The present invention relates to an in-situ multilayered tablet comprising at least one polymer layers and at least one drug layers wherein the said layers are physically separated from each other. After coming in contact with biological and/or aqueous fluids at least one of the polymer layers rapidly swells and sticks to one or more drug layers to form an in-situ multilayered tablet. Further, the polymer layer may optionally comprise a drug. Furthermore, the present invention relates to the processes for preparing said in-situ multilayered tablets.
    Type: Application
    Filed: January 23, 2013
    Publication date: December 25, 2014
    Applicant: RANBAXY LABORATORIES LIMITED
    Inventors: Kumaravel Vivek, Anuj Kumar Fanda, Murali Krishna, Ravish Kumar Sharma, Kanwarpreet Singh Bakshi, Romi Barat Singh, Ajay Kumar Singla
  • Patent number: 8911765
    Abstract: A biodegradable, flexible covering for a breast implant is provided which comprises one or more biodegradable polymer layers dimensioned and shaped to cover at least a portion of the breast implant. The implant can be inserted into an opening of the covering immediately prior to surgery, but alternate configurations and times of insertion are contemplated as well as open or sheet type devices. The coverings can optionally contain one or more drugs for delivery at the surgical site, particularly for treating or preventing infection, pain, inflammation, capsular contracture, scarring or other complications associated with breast augmentation or breast reconstruction.
    Type: Grant
    Filed: March 28, 2008
    Date of Patent: December 16, 2014
    Assignee: Tyrx, Inc.
    Inventors: Arikha Moses, Satish Pulapura, Qing Ge, Sarita Nethula, Irene Shatova, Archana Rajaram
  • Patent number: 8911775
    Abstract: Disclosed is a pH-sensitive block copolymer that forms polyionic complex micelles. The block copolymer is prepared by copolymerization of (a) a polyethylene glycol compound, (b) a poly(amino acid) compound, and (c) a heterocyclic alkyl amine compound having the ability to induce the formation of ionic complexes. Further disclosed is a drug or protein carrier using the block copolymer.
    Type: Grant
    Filed: July 23, 2010
    Date of Patent: December 16, 2014
    Assignee: Sungkyunkwan University Foundation for Corporate
    Inventors: Doo Sung Lee, Bong Sup Kim, Jung Hee Lee, Guanghui Gao
  • Patent number: 8906887
    Abstract: The present invention is directed to a compound represented by Structural Formula (A): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (A) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (A) and its therapeutic use.
    Type: Grant
    Filed: August 7, 2009
    Date of Patent: December 9, 2014
    Assignee: Tetraphase Pharmaceuticals, Inc.
    Inventors: Jingye Zhou, Xiao-Yi Xiao, Louis Plamondon, Diana Katharine Hunt, Roger B. Clark, Robert B. Zahler
  • Publication number: 20140349977
    Abstract: Methods for determining if a patient has, or is at risk of having, and autism spectrum disorder by detecting epigenetic changes in the genome of the patient. For example, a method can comprise determining the methylation status of one or more genes in a blood sample.
    Type: Application
    Filed: October 12, 2012
    Publication date: November 27, 2014
    Applicant: ZYMO RESEARCH CORPORATION
    Inventors: Xueguang Sun, Xiyu Jia
  • Publication number: 20140349938
    Abstract: The invention features methods of diagnosing a subject as having, or at risk of developing ALS by determining the frequency of Gems in cells obtained from the subject. These methods include diagnosing the severity or monitoring the progression of ALS by determining the Gem frequency in a subject. Also, the invention features methods of identifying compounds useful for the treatment of ALS as well as methods for the treatment of ALS.
    Type: Application
    Filed: June 1, 2012
    Publication date: November 27, 2014
    Applicant: President and Fellows of Harvard College
    Inventors: Robin Reed, Shi Chen, Yong Yu, Tomohiro Yamazaki
  • Patent number: 8895047
    Abstract: Implantable catheters are provided which comprise an antimicrobial agent incorporated in a coating or bulk distributed, in combination with a fibrinolytic agent incorporated in a top coating.
    Type: Grant
    Filed: May 21, 2008
    Date of Patent: November 25, 2014
    Assignee: Arrow International, Inc.
    Inventors: Nisha Gupta, Joel Rosenblatt, Daniel J. Spangler
  • Publication number: 20140343020
    Abstract: A method for modulating RNA with tetracycline compounds is described.
    Type: Application
    Filed: March 7, 2014
    Publication date: November 20, 2014
    Applicant: PARATEK PHARMACEUTICALS, INC
    Inventors: Stuart B. Levy, Michael P. Draper, Mark L. Nelson, Graham Jones
  • Publication number: 20140335047
    Abstract: The present invention provides a particulate delivery system comprising an extracted yeast cell wall comprising beta-glucan, a payload molecule and a payload trapping molecule. The invention further provides methods of making and methods of using the particulate delivery system.
    Type: Application
    Filed: November 6, 2013
    Publication date: November 13, 2014
    Applicant: UNIVERSITY OF MASSACHUSETTS
    Inventor: Gary R. OSTROFF
  • Publication number: 20140323391
    Abstract: Disclosed herein are biomarkers useful for identifying and/or classifying bacterial infections in a subject.
    Type: Application
    Filed: March 15, 2014
    Publication date: October 30, 2014
    Applicant: Duke University
    Inventors: Ephraim Tsalik, Vance Fowler, Christopher W. Woods, Joseph E. Lucas, Geoffrey S. Ginsburg, Sun Hee Ahn
  • Patent number: 8871184
    Abstract: A topical therapeutic hydrophobic breakable composition includes a carrier comprising (a) about 60% to about 99% by weight of at least one hydrophobic oil; (b) at least one viscosity-modifying agents selected from the group consisting of a fatty alcohol, a fatty acid and a wax; and (c) a tetracycline antibiotic, characterized in that at least part of the tetracycline antibiotic is suspended in the composition; the viscosity of the composition is at least about 30% higher than the viscosity of the carrier without the tetracycline antibiotic; and is higher than the viscosity of the hydrophobic oil and the tetracycline antibiotic without the viscosity modifying agents; and the amount of viscosity modifying agents can optionally be reduced by at least an amount by weight that would have increased the viscosity of the carrier without the tetracycline antibiotic by at least 30%; wherein the tetracycline is chemically stable in the composition for at least six months; wherein more than about 90% of the tetracycline
    Type: Grant
    Filed: October 1, 2010
    Date of Patent: October 28, 2014
    Assignee: Foamix Ltd.
    Inventors: Dov Tamarkin, Elana Gazal, Yohan Hazot, David Schuz, Rita Keynan, Nukri Papiashvili
  • Publication number: 20140314798
    Abstract: The present invention concerns methods and compositions for treatment and determination of the presence or likelihood of an individual to have an ocular surface inflammation. In specific embodiments, a sample from the individual is assayed for the expression level of three or more genes, including IL-6, MMP3, MMP9, IFNy, SPRR-IA, HLA-DRA, MUC5AC, K7, and IL17A. Treatment is provided to an individual with ocular surface inflammation based upon the gene analysis.
    Type: Application
    Filed: October 19, 2012
    Publication date: October 23, 2014
    Inventors: Stephen C. Pflugfelder, Cintia S. De Paiva, Rosa M. Corrales Herran, De-Quan Li
  • Patent number: 8865139
    Abstract: A topical therapeutic hydrophobic breakable composition includes a carrier comprising (a) about 60% to about 99% by weight of at least one hydrophobic oil; (b) at least one viscosity-modifying agents selected from the group consisting of a fatty alcohol, a fatty acid and a wax; and (c) a tetracycline antibiotic, characterized in that at least part of the tetracycline antibiotic is suspended in the composition; the viscosity of the composition is at least about 30% higher than the viscosity of the carrier without the tetracycline antibiotic; and is higher than the viscosity of the hydrophobic oil and the tetracycline antibiotic without the viscosity modifying agents. The tetracycline is chemically stable in the composition for at least six months; wherein more than about 90% of the tetracycline has not broken down. The composition is packaged as a breakable foam that breaks easily upon application of shear force.
    Type: Grant
    Filed: July 9, 2014
    Date of Patent: October 21, 2014
    Assignee: Foamix Pharmaceuticals Ltd.
    Inventors: Dov Tamarkin, Elana Gazal, Irakliy Papiashvili, Yohan Hazot, David Schuz, Rita Keynan
  • Patent number: 8865686
    Abstract: The instant invention is directed towards tetracycline compositions, and methods of inhibiting Tdp1 activity, and methods of treating Tdp1-associated disorders.
    Type: Grant
    Filed: September 29, 2008
    Date of Patent: October 21, 2014
    Assignee: The United States of America, as Represented by the Secretary, Dept. of Health and Human Services
    Inventors: Yves Pommier, Laurent Thibaut, Christophe Marchand
  • Publication number: 20140309185
    Abstract: This document relates to inhibitors of G protein coupled receptor 6 kinase (GRK6) polypeptides as well as methods and materials for using such inhibitors to treat hematological malignancies, inflammation diseases, and autoimmune disorders.
    Type: Application
    Filed: October 26, 2012
    Publication date: October 16, 2014
    Inventors: Alexander Keith Stewart, Artem Plekhov, Robert Greenhouse
  • Publication number: 20140309198
    Abstract: An improved method for treating acne is described. The method involves 16-week, once daily, oral administration of about 40 mg doxycycline in a pharmaceutical composition containing about 30 mg doxycycline in an immediate release portion and about 10 mg doxycycline in a delayed release portion. It was surprisingly discovered that the 16-week, once daily, oral administration of about 40 mg doxycycline has achieved same or superior efficacy than that of 100 mg doxycycline, but with a significant reduction in adverse events.
    Type: Application
    Filed: April 4, 2014
    Publication date: October 16, 2014
    Inventors: Vasant Kumar MANNA, Sandrine SEGURA, Ludovic BUSSARD, Jean-Pierre ETCHEGARAY, Philip FREIDENREICH
  • Publication number: 20140309199
    Abstract: The present invention pertains, at least in part, to novel 9-substituted minocycline compounds. These minocycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and minocycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.
    Type: Application
    Filed: June 27, 2014
    Publication date: October 16, 2014
    Inventors: Mark L. Nelson, Roger Frechette, Mohamed Y. Ismail, Laura Honeyman, Todd Bowser, Beena Bhatia
  • Publication number: 20140303100
    Abstract: This invention pertains to dental care compositions with antimicrobial benefits. In particular, the invention provides for compositions of oral tissue-adherent salts that release biocidal ions on a controlled release basis and thereby provide and maintain an essentially uniform concentration of biocidal ions above the MBC or MIC of the target bacteria at the site of application in the mouth for an extended period of time. The compositions are useful for treating or preventing oral diseases resulting from bacteria, fungal or yeast infections, such as caries, gingivitis, periodontal disease and candidiasis.
    Type: Application
    Filed: June 25, 2014
    Publication date: October 9, 2014
    Inventors: Anthony Errol Winston, Richard F. Stockel, Anthony Joseph Sawyer
  • Publication number: 20140303101
    Abstract: This invention pertains to dental care compositions with antimicrobial benefits. In particular, the invention provides for compositions of oral tissue-adherent salts that release biocidal ions on a controlled release basis and thereby provide and maintain an essentially uniform concentration of biocidal ions above the MBC or MIC of the target bacteria at the site of application in the mouth for an extended period of time. The compositions are useful for treating or preventing oral diseases resulting from bacteria, fungal or yeast infections, such as caries, gingivitis, periodontal disease and candidiasis.
    Type: Application
    Filed: June 25, 2014
    Publication date: October 9, 2014
    Inventors: Anthony Errol Winston, Richard F. Stockel, Anthony Joseph Sawyer
  • Publication number: 20140287063
    Abstract: Provided are methods of determining a response to a chemotherapeutic agent in a subject with ovarian cancer, comprising: determining a RNA integrity value of a sample comprising ovarian cancer cell RNA from the subject after the subject has received one or more doses of the chemotherapeutic agent; wherein a low RNA integrity value and/or RNA degradation of the cancer cell RNA is indicative that the cancer is responding to the chemotherapeutic agent and/or a high RNA integrity value and/or stable RNA integrity of the ovarian cancer cell RNA is indicative that the cancer is resistant to the chemotherapeutic agent.
    Type: Application
    Filed: August 10, 2011
    Publication date: September 25, 2014
    Applicants: RNA DIAGNOSTICS INC., LAURENTIAN UNIVERSITY OF SUDBURY
    Inventors: Amadeo Mark Parissenti, Baoqing Guo, Kenneth Pritzker, Laura Pritzker
  • Publication number: 20140274969
    Abstract: A dosing regime for providing therapy for a neurological trauma such as spinal cord injury in a human subject. The dosing regime comprises intravenous administration of a plurality of minocycline doses for a 7-day period at 12-h intervals such that a steady state level of minocycline is reached and maintained in a subject's serum and/or cerebrospinal fluid after administration of three minocycline doses. An initial minocycline dose of at least 800 mg is preferably administered within 12 h after an occurrence of the neurological trauma. The minocycline dosage is sequentially tapered to 400 mg and then maintained at 400 mg for the remainder of the 7-day treatment period.
    Type: Application
    Filed: March 15, 2013
    Publication date: September 18, 2014
    Applicant: RICK HANSEN INSTITUTE
    Inventors: Steven CASHA, John HURLBERT, Voon Wee YONG
  • Publication number: 20140274925
    Abstract: Disclosed herein are compositions and methods for diagnosing, treating, and monitoring Lyme disease.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 18, 2014
    Inventors: Chenggang Jin, Gottfried H. Kellermann
  • Publication number: 20140274905
    Abstract: The present invention generally relates to methods of modulating Cav1.2 channels and Cav1.2 channel activators.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 18, 2014
    Applicant: Duke University
    Inventors: Geoffrey S. Pitt, Adam S. Barnett, Xinhe Yin
  • Publication number: 20140271834
    Abstract: The present invention is directed to a pharmaceutical composition in unit dose form for orally delivering doxycycline to a human, the pharmaceutical composition comprising: a capsule, wherein the capsule is coated with a delayed release layer; wherein the delayed release layer comprises about 4 to 6 mg of doxycycline monohydrate and a binding agent, and wherein the delayed release layer is coated with an enteric coating; wherein the enteric coating dissolves at pH of about 5 to 6, and wherein the enteric coating is coated with an immediate release layer; wherein the immediate release layer comprises about 32 mg of doxycycline monohydrate and a binding agent, wherein the relative mean Cmax of the pharmaceutical composition is within 80.00% to 125.00% of a Cmax value of 510±220.7 ng/mL, after administration of a single dose of the pharmaceutical composition to humans in a fasting state; and wherein the relative mean AUC(0-?) of the pharmaceutical composition is within 80.00% to 125.
    Type: Application
    Filed: October 16, 2013
    Publication date: September 18, 2014
    Applicants: Cerovene, Inc., Galderma S.A.
    Inventors: Jean-Pierre Etchegaray, Nathalie Wagner, Manish S. Shah, Ray J. Difalco
  • Publication number: 20140271845
    Abstract: Pharmaceutical compositions in unit dose form comprising a hollow substrate and one or more coatings on the hollow substrate, wherein at least one coating comprises at least one active pharmaceutical ingredient, and methods of making the same are provided.
    Type: Application
    Filed: March 18, 2014
    Publication date: September 18, 2014
    Applicant: Cerovene, Inc.
    Inventors: Manish S. SHAH, Ray J. DiFalco
  • Publication number: 20140274971
    Abstract: Methods, devices and systems are disclosed for chemically bonding antibiotics to selected substrate materials which are not dissolved in normal physiological processes so that high local concentrations can be achieved during the inflammatory response. The antibiotics will remain permanently bonded to the substrate material until an infection occurs which releases the antibiotic in high concentrations to help control the infection. The high local concentrations may be much higher than systemic toxic levels, and can never reach toxic levels because the local dose is much less than needed to reach systemic toxicity if completely dissolved.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicant: Osteoceramics, Inc.
    Inventor: Thomas D. McGee
  • Publication number: 20140274970
    Abstract: The present disclosure provides novel controlled release pharmaceutical dosage form, methods of making the same, and methods of using the same to treat dermatological conditions.
    Type: Application
    Filed: May 8, 2013
    Publication date: September 18, 2014
    Inventors: Sajeev CHANDRAN, Shirishkumar KULKARNI, Pravin Meghrajji BHUTADA, Ashish Ashokrao DESHMUKH, Douglas BAKAN, Mitchell WORTZMAN
  • Publication number: 20140256661
    Abstract: The present invention relates to a pharmaceutical composition, in particular a composition formulated for enema administration, wherein the composition comprises metronidazole or a pharmacologically acceptable derivative thereof in an amount to effectively treat both acute and chronic pouchitis and/or proctitis.
    Type: Application
    Filed: July 12, 2012
    Publication date: September 11, 2014
    Inventor: David Nigel Armstrong
  • Patent number: 8828977
    Abstract: The present invention provides a method for treating a vertebrate subject suffering from a degenerative disc disease by administering an inhibitor of a matrix metalloprotease (MMP) to the subject in an amount effective to treat the subject.
    Type: Grant
    Filed: February 16, 2007
    Date of Patent: September 9, 2014
    Assignee: Discogen, LLC
    Inventor: Peter A. Zahos
  • Publication number: 20140227272
    Abstract: The present invention relates in essence to a compound which decreases or inhibits the binding of mammalian T-cells to mammalian endothelial cells for use in a method of prophylaxis and/or amelioration and/or treatment of clinical adverse events caused by therapy which comprises re-directing of T-cells against target cells in a patient. Methods of treatment of patients having or being at risk of clinical adverse events caused by therapy which comprises re-directing of T-cells against target cells are also contemplated.
    Type: Application
    Filed: February 8, 2014
    Publication date: August 14, 2014
    Applicant: AMGEN RESEARCH (MUNICH) GMBH
    Inventors: Peter Kufer, Dirk Nagorsen, Juergen Scheele, Gerhard Zugmaier, Matthias Klinger, Patrick Hoffmann, Virginie Naegele, Elaine-Pashupati Dopfer
  • Patent number: 8802707
    Abstract: This invention is a method of killing the stealthy intra-cellular bacteria which are key to the pathogenesis Cancers. These very tiny L-form Cell-Wall-Deficient (CWD) antibiotic-resistant bacteria live within the cytoplasm of cells, including the phagocytic cells (e.g. monocytes, macrophages, lymphocytes, neutrophils and polymorphonuclear cells) of the immune system itself. The cellular proliferation in Cancer is catalysed the action of the same tiny L-form bacteria. They cause the cell nucleus to release mRNA signaling the Th1 cytokine cascade without the need for conventional signaling via, for example, CD4+T -Lymphocytes. Some of these Cytokines and Chemokines, including, without limitation, Cellular Adhesion Molecule (CAM), create the environment which allows the cellular proliferation to start, and then allows the cancerous growth to gain a foothold in the body. Killing these stealthy pathogens removes the environment needed to initiate and feed the cellular proliferation commonly called ‘Cancer’.
    Type: Grant
    Filed: July 31, 2006
    Date of Patent: August 12, 2014
    Inventor: Trevor Gordon Marshall
  • Publication number: 20140221320
    Abstract: The method of the present application is directed towards a method for suppressing an allergic response in response to an allergic trigger. This method comprises the following steps; applying, topically, to an affected area an effective amount of a minocycline composition so that the minocycline composition contacts the affected area for an effective amount of time and removing the minocycline composition from the affected area.
    Type: Application
    Filed: July 6, 2012
    Publication date: August 7, 2014
    Applicant: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
    Inventors: Rauno Olev Joks, Helen G. Durkin
  • Publication number: 20140220098
    Abstract: In some embodiments, a device (102) may include a mesh having at least one bioresorbable polymer coating. The coating may comprise at least one active agent which is eluted over time. The device (102) may at least partially cover at least a portion of an implanted transdermal medical device (100).
    Type: Application
    Filed: July 20, 2012
    Publication date: August 7, 2014
    Applicant: TYRX, INC.
    Inventors: Daniel Jeremy Lerner, William McJames, Randy Mansfield, Robert S. White
  • Publication number: 20140221922
    Abstract: Bioactive hydroforming luminal liner compositions are formed of an absorbable crystalline amphiphilic polyether-ester-urethane dissolved in a liquid derivative of a polyether glycol that undergoes transformation into a tissue-adhering, resilient interior cover or liner for the controlled release of its bioactive payload at clinically compromised conduits in humans as in the case of bacteria- and yeast-infected vaginal canals, esophagi, and arteries following angioplasty.
    Type: Application
    Filed: April 7, 2014
    Publication date: August 7, 2014
    Applicant: POLY-MED, INC.
    Inventors: Shalaby W. Shalaby, David Ingram, Georgios Hilas, Sheila Nagatomi